ZBH-RM.ME Stock Analysis
ZB
Neutral
Based on Eyestock quantitative analysis, ZBH-RM.ME`s fundamental data and valuation indicate an investment grade of Neutral at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly undervalued
Market cap $B
21.956
Dividend yield
0.89 %
Shares outstanding
210.06 B
Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The company is headquartered in Warsaw Indiana, Indiana and currently employs 18,000 full-time employees. The company went IPO on 2001-07-25. Its segments include Americas, EMEA, and Asia Pacific. The firm designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; craniomaxillofacial and thoracic (CMFT) products; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. Its other product category primarily includes its robotic, surgical and bone cement products. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee, and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System, and G7 Acetabular System. Its S.E.T. product category includes sports medicine, biologics, foot and others.